Cargando…

Neoadjuvant Therapy for Locally Advanced Esophageal Cancers

Esophageal carcinoma is one of the most aggressive malignant diseases. At present, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy are regarded as the standard modalities for the treatments of locally advanced esophageal cancers based on several landmark trials. However, the optimal regim...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Runkai, Qiu, Zhenbin, Zheng, Chunwen, Zeng, Ruijie, Chen, Wanxian, Wang, Simeng, Li, Enmin, Xu, Yiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021527/
https://www.ncbi.nlm.nih.gov/pubmed/35463306
http://dx.doi.org/10.3389/fonc.2022.734581
_version_ 1784689850629226496
author Huang, Runkai
Qiu, Zhenbin
Zheng, Chunwen
Zeng, Ruijie
Chen, Wanxian
Wang, Simeng
Li, Enmin
Xu, Yiwei
author_facet Huang, Runkai
Qiu, Zhenbin
Zheng, Chunwen
Zeng, Ruijie
Chen, Wanxian
Wang, Simeng
Li, Enmin
Xu, Yiwei
author_sort Huang, Runkai
collection PubMed
description Esophageal carcinoma is one of the most aggressive malignant diseases. At present, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy are regarded as the standard modalities for the treatments of locally advanced esophageal cancers based on several landmark trials. However, the optimal regimen, radiation dose, and surgical intervals are uncertain and the rate of recurrence after neoadjuvant therapy is high. Patients receiving neoadjuvant therapy and reaching a pathological complete response have been reported to have a better survival benefit and a fewer recurrence risk than those non-pathological complete responses. Nevertheless, less than half of patients will reach a pathological complete response after neoadjuvant therapy, and the methods to evaluate the efficacy after neoadjuvant therapy accurately are limited. Immune checkpoint inhibitors have been recommended for the treatments of advanced esophageal cancers. Recently, research has been beginning to evaluate the safety and efficacy of immunotherapy combined with neoadjuvant therapy. Here, we will review and discuss the development of the neoadjuvant therapy of locally advanced esophageal cancers and unsolved clinical problems.
format Online
Article
Text
id pubmed-9021527
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90215272022-04-22 Neoadjuvant Therapy for Locally Advanced Esophageal Cancers Huang, Runkai Qiu, Zhenbin Zheng, Chunwen Zeng, Ruijie Chen, Wanxian Wang, Simeng Li, Enmin Xu, Yiwei Front Oncol Oncology Esophageal carcinoma is one of the most aggressive malignant diseases. At present, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy are regarded as the standard modalities for the treatments of locally advanced esophageal cancers based on several landmark trials. However, the optimal regimen, radiation dose, and surgical intervals are uncertain and the rate of recurrence after neoadjuvant therapy is high. Patients receiving neoadjuvant therapy and reaching a pathological complete response have been reported to have a better survival benefit and a fewer recurrence risk than those non-pathological complete responses. Nevertheless, less than half of patients will reach a pathological complete response after neoadjuvant therapy, and the methods to evaluate the efficacy after neoadjuvant therapy accurately are limited. Immune checkpoint inhibitors have been recommended for the treatments of advanced esophageal cancers. Recently, research has been beginning to evaluate the safety and efficacy of immunotherapy combined with neoadjuvant therapy. Here, we will review and discuss the development of the neoadjuvant therapy of locally advanced esophageal cancers and unsolved clinical problems. Frontiers Media S.A. 2022-04-07 /pmc/articles/PMC9021527/ /pubmed/35463306 http://dx.doi.org/10.3389/fonc.2022.734581 Text en Copyright © 2022 Huang, Qiu, Zheng, Zeng, Chen, Wang, Li and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Huang, Runkai
Qiu, Zhenbin
Zheng, Chunwen
Zeng, Ruijie
Chen, Wanxian
Wang, Simeng
Li, Enmin
Xu, Yiwei
Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
title Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
title_full Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
title_fullStr Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
title_full_unstemmed Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
title_short Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
title_sort neoadjuvant therapy for locally advanced esophageal cancers
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021527/
https://www.ncbi.nlm.nih.gov/pubmed/35463306
http://dx.doi.org/10.3389/fonc.2022.734581
work_keys_str_mv AT huangrunkai neoadjuvanttherapyforlocallyadvancedesophagealcancers
AT qiuzhenbin neoadjuvanttherapyforlocallyadvancedesophagealcancers
AT zhengchunwen neoadjuvanttherapyforlocallyadvancedesophagealcancers
AT zengruijie neoadjuvanttherapyforlocallyadvancedesophagealcancers
AT chenwanxian neoadjuvanttherapyforlocallyadvancedesophagealcancers
AT wangsimeng neoadjuvanttherapyforlocallyadvancedesophagealcancers
AT lienmin neoadjuvanttherapyforlocallyadvancedesophagealcancers
AT xuyiwei neoadjuvanttherapyforlocallyadvancedesophagealcancers